Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pennsylvania State University

Latest From Pennsylvania State University

Liquid Biopsy On Course To Transform Cancer Management

Liquid biopsies look set to revolutionize the management of cancer patients.  A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.

Cancer Business Strategies

How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

Medical Device United States

REVA: In Bioresorbable Stents, As Things Change, Will The Value Remain The Same?

REVA Medical started almost 14 years ago as a bare metal stent company, only to run into the drug-eluting stent (DES) revolution. In response to the DES boom, the company reinvented itself as a bioresorbable stent company and then added a drug-eluting capability. However, until the late-stent thrombosis risk of DES emerged in 2006, bioresorbable stents were largely irrelevant. REVA has survived the ups and downs of the device financing environment by adopting creative solutions, including an evolving relationship with a strategic partner and ultimately an Australian IPO. The company is just now reentering the clinic with its pivotal trial, which is both a testament to its perseverance and a sign of the many challenges still ahead, not the least of which being whether REVA’s innovation will ultimately be rewarded.

Medical Device Innovation

AF Ablation: Finding the Right Mix

For a number of reasons, 2009 was a big year for the atrial fibrillation ablation market. Early in the year, Biosense Webster received FDA approval for its radiofrequency ablation catheter, the first such device to launch in the US with a specific AF indication. That approval was much more than just a landmark event for J&J; it changed the landscape of the AF industry, reinvigorating interest in the funding and development of new catheter-based technologies--a trend that has extended through to 2010 and will likely continue in the years ahead.
Medical Device
See All